Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder
The severity of the ongoing opioid crisis, recently exacerbated by the COVID-19 pandemic, emphasizes the importance for individuals suffering from opioid use disorder (OUD) to have access to and receive efficacious, evidence-based treatments. Optimal treatment of OUD should aim at blocking the effec...
Main Authors: | Celine M. Laffont, Eliford Ngaimisi, Mathangi Gopalakrishnan, Vijay Ivaturi, Malcolm Young, Mark K. Greenwald, Christian Heidbreder |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-11-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.1052113/full |
Similar Items
-
Cannabidiol Effect on Cue-Induced Craving for Individuals with Opioid Use Disorder Treated with Buprenorphine: A Small Proof-of-Concept Open-Label Study
by: Joji Suzuki, et al.
Published: (2022-08-01) -
A randomized clinical trial on the effects of bupropion and buprenorphine on the reduction of methamphetamine craving
by: Jamshid Ahmadi, et al.
Published: (2019-07-01) -
Beneficial Effects of Opioid Rotation to Buprenorphine/Naloxone on Opioid Misuse, Craving, Mental Health, and Pain Control in Chronic Non-Cancer Pain Patients with Opioid Use Disorder
by: Arnt F. A. Schellekens, et al.
Published: (2021-08-01) -
County-level neonatal opioid withdrawal syndrome rates and real-world access to buprenorphine during pregnancy: An audit (“secret shopper”) study in Missouri
by: Bronwyn S. Bedrick, et al.
Published: (2024-03-01) -
Operational definition of precipitated opioid withdrawal
by: Kelly E. Dunn, et al.
Published: (2023-04-01)